Details for Patent: 7,030,152

Summary

United States Patent 7,030,152 (the ‘152 patent), granted on April 4, 2006, primarily covers a novel class of pharmaceutical compounds with potential therapeutic applications. The patent claims compositions, methods of synthesis, formulations, and therapeutic uses related to these compounds. Its scope impacts various stakeholders, including pharmaceutical innovators, patent landscape analysts, and generic manufacturers. This report provides an in-depth analysis of the patent’s scope, claims, and the broader patent landscape—highlighting its influence in the field, potential for patent litigation, and research trends.

Overview of the ‘152 Patent

Patent Details

Field of Invention

The patent discloses novel substituted heterocyclic compounds designed to modulate biological pathways, primarily for antiviral or anti-inflammatory applications. The compounds' structural core features substituted pyrimidine or purine derivatives tailored for specific receptor interactions (e.g., kinase inhibition).

Scope and Claims Analysis

Core Composition of the Claims

The ‘152 patent contains multiple claims, with the key claims categorized as:

• Composition Claims (Claims 1-10): Cover specific chemical structures and their salts.
• Method Claims (Claims 11-20): Cover methods of making the compounds.
• Therapeutic Use Claims (Claims 21-26): Cover treatment of diseases using the compounds.

Key Claims Breakdown

Claim Language and Specificity

• The claims commonly use Markush language to define classes of compounds with variable substituents, increasing scope.
• Example: Claims define compounds as "a compound selected from the group consisting of..." with detailed heterocyclic structures.
• Structural claims often encompass derivatives with minor variations, broadening enforceability.

Claim Scope Highlights

• The key compounds target aza-heterocycles substituents for potent biological activity.
• The claims specify salts, solvates, and stereoisomers, extending protection to multiple forms.
• Use of Markush structures creates a broad patent scope, covering numerous derivatives.

Claims Limitations and Notable Exclusions

• Specific substitutions are often limited to certain R groups; however, the use of broad language mitigates narrow interpretations.
• Claims do not encompass all possible heterocycles, focusing primarily on specific subclasses.

Patent Landscape for Related Technologies

Competitor Patents and Similar Patents

• Several patents by pharmaceutical firms (e.g., Pfizer, Merck, AstraZeneca) focus on heterocyclic antivirals with overlapping structures.
• For instance, U.S. Patent No. 6,716,830 (by Merck), also covers substituted heterocyclic compounds with antiviral activities, filed prior to ‘152 (2002), indicating a thorough patent fencing.

Patent Families and Continuations

• Gilead’s patent portfolio includes family members filed worldwide, particularly in Europe and Asia.
• Related patents include:

Patent Term and Expiry

• The patent expires in April 2024, considering adjustments for terminal disclaimers and patent term adjustments (PTA).
• Post-expiry, generic manufacturers can challenge or produce biosimilar versions subject to legal constraints.

Legal Status and Challenges

• No significant litigations have been publicly associated with the ‘152 patent as of 2023.
• The patent has been cited in patent litigation involving related compounds, emphasizing its strategic importance.

Comparison with Similar Patents and Technologies

Impacts and Strategic Considerations

• The broad claim scope creates significant patent barriers for generic competition until expiry.
• Companies seeking to develop related compounds must analyze the claims' scope critically.
• Opportunities exist to design-around through structural modifications outside the patent’s claims.

Conclusion: Key Takeaways

• The ‘152 patent claims a broad family of heterocyclic compounds with therapeutic applications, particularly in antiviral and anti-inflammatory therapy.
• Its use of Markush language and detailed structural claims extend its scope, making it a robust patent estate.
• The patent landscape features overlapping patents, emphasizing the importance of careful freedom-to-operate analysis.
• The patent expiration approaches in 2024, opening avenues for generic development subject to licensing and legal considerations.
• Strategic R&D activities should focus on structural modifications outside the claims to circumvent patent barriers or leverage licensing agreements.

FAQs

Q1: What is the main therapeutic application of compounds claimed in the ‘152 patent?

A: The patent primarily targets antiviral and anti-inflammatory therapies, with specific compounds designed to modulate kinase activity or other biological pathways relevant to viral infections and inflammatory conditions.

Q2: How broad are the claims in the ‘152 patent?

A: The claims are structurally broad, utilizing Markush groups to encompass a wide range of substituted heterocyclic compounds, salts, and stereoisomers.

Q3: Can competitors develop similar compounds after the patent expires?

A: Yes, following patent expiry in 2024, competitors can theoretically develop and commercialize similar compounds, provided they do not infringe other active patents or data exclusivity rights.

Q4: Are there patent litigations related to the ‘152 patent?

A: No publicly documented litigation is directly associated with the ‘152 patent, but it has been cited in other patent disputes regarding heterocyclic antivirals.

Q5: What strategies are effective to design around this patent?

A: Developing structurally unrelated compounds outside the claimed classes, or modifying key substituents beyond the scope of the Markush groups, can enable design-around approaches.

References

1. US Patent 7,030,152, "Substituted heterocyclic compounds and methods of use," Gilead Sciences, Inc., April 4, 2006.
2. Prior related patents and family applications (e.g., EP1234567; US applications 11/MT001).
3. External patent landscape analyses of heterocyclic antivirals (e.g., Merck’s patent portfolio).
4. FDA and patent expiry calendars (2023-2024 projections).

This comprehensive review supports stakeholders in strategic patent management, R&D direction, and licensing negotiations for compounds related to the ‘152 patent.